|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 4550 Montgomery Avenue |
Address2 | Suite 1100N |
City | Bethesda |
State | MD |
Zip Code | 20814 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 60195-12
|
||||||||
|
6. House ID# 353460000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Mary Dwight, SVP for Policy & CF Community Affairs |
Date | 10/21/2019 5:11:46 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 2740: Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020; provisions related to funding for the Health and Human Services and related agencies
H.R. 3055: Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020; provisions related to funding for the Food and Drug Administration and related agencies
H.R. 4378 - Continuing Appropriations Act, 2020, and Health Extenders Act of 2019; provisions related to funding for the Health and Human Services, Food and Drug Administration and related agencies
S. 2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020; provisions related to funding for the Food and Drug Administration and related agencies
Labor, Health and Human Services (LHHS) appropriations for Fiscal Year 2020 draft; provisions related to funding for the Health and Human Services and related agencies
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Zoe |
Aldrich |
|
|
|
Daniel |
Cramer |
|
|
|
Jonathan |
Daniels |
|
|
|
Mary |
Dwight |
|
|
|
Victoria |
Gemme |
|
|
|
Katherine |
Haswell |
|
|
|
Sara |
Singleton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.J. Res. 74: Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers"; all provisions
H.R. 3 - Lower Drug Costs Now Act of 2019; all provisions
H.R. 986: Protecting Americans with Preexisting Conditions Act of 2019; all provisions
H.R. 987: Strengthening Health Care and Lowering Prescription Drug Costs Act; all provisions
H.R. 1010: To provide that the rule entitled Short-Term, Limited Duration Insurance shall have no force or effect; all provisions
H.R. 1425: State Health Care Premium Reduction Act; all provisions
H.R. 1868: Health Care Affordability Act of 2019; all provisions
H.R. 1870: Family Health Care Affordability Act of 2019; all provisions
H.R. 2296: FAIR Drug Pricing Act of 2019; all provisions
H.R. 2507: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions
Ways & Means and Energy & Commerce discussion draft on capping Medicare Part D out-of-pocket costs; all provisions
S.J. Res. 52: A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers"; all provisions
S. 466: Protecting Americans with Pre-existing Conditions Act of 2019; all provisions
S. 475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019; all provisions
S. 961: Improving Health Insurance Affordability Act of 2019; all provisions
S. 1556: No Junk Plans Act; all provisions
S. 1712: Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019; all provisions
S. 1895: Lower Health Care Costs Act; all provisions
S. 1935: Family Coverage Act; all provisions
S. 2158: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions
S. 2543 - Prescription Drug Pricing Reduction Act of 2019; all provisions
The Medical Records Access Fairness Act draft; all provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Zoe |
Aldrich |
|
|
|
Daniel |
Cramer |
|
|
|
Jonathan |
Daniels |
|
|
|
Mary |
Dwight |
|
|
|
David |
Elin |
|
|
|
Victoria |
Gemme |
|
|
|
Katherine |
Haswell |
|
|
|
Sara |
Singleton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
General discussions regarding Medical Deferred Action
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Daniels |
|
N/A |
|
Mary |
Dwight |
|
N/A |
|
Katherine |
Haswell |
|
N/A |
|
Leslie |
Powell |
|
N/A |
|
Sara |
Singleton |
|
N/A |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
H.J. Res. 74: Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers"; all provisions
H.R. 986: Protecting Americans with Preexisting Conditions Act of 2019; all provisions
H.R. 987: Strengthening Health Care and Lowering Prescription Drug Costs Act; all provisions
H.R. 1010: To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect; all provisions
H.R. 1425: State Health Care Premium Reduction Act; all provisions
H.R. 1868: Health Care Affordability Act of 2019; all provisions
H.R. 1870: Family Health Care Affordability Act of 2019; all provisions
Ways & Means and Energy & Commerce discussion draft on capping Medicare Part D out-of-pocket costs; all provisions
S.J. Res. 52: A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers"; all provisions
S. 466: Protecting Americans with Pre-existing Conditions Act of 2019; all provisions
S. 475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019; all provisions
S. 961: Improving Health Insurance Affordability Act of 2019; all provisions
S. 1556: No Junk Plans Act; all provisions
S. 1712: Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019; all provisions
S. 1895: Lower Health Care Costs Act; all provisions
S. 1935: Family Coverage Act; all provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Zoe |
Aldrich |
|
N/A |
|
Daniel |
Cramer |
|
N/A |
|
Jonathan |
Daniels |
|
N/A |
|
Mary |
Dwight |
|
N/A |
|
David |
Elin |
|
N/A |
|
Lisa |
Feng |
|
N/A |
|
Victoria |
Gemme |
|
N/A |
|
Katherine |
Haswell |
|
N/A |
|
Sara |
Singleton |
|
N/A |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R. 3: Lower Drug Costs Now Act of 2019; all provisions
H.R. 987: Strengthening Health Care and Lowering Prescription Drug Costs Act; all provisions
H.R. 2507: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions
H.R. 2740: Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020; provisions related to funding for the Health and Human Services and related agencies
H.R. 3055: Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020; provisions related to funding for the Food and Drug Administration and related agencies
H.R. 4378 - Continuing Appropriations Act, 2020, and Health Extenders Act of 2019; provisions related to funding for the Health and Human Services and related agencies
S. 2158: Newborn Screening Saves Lives Reauthorization Act of 2019; all provisions
S. 2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020; provisions related to funding for the Food and Drug Administration and related agencies
S. 2543 - Prescription Drug Pricing Reduction Act of 2019; all provisions
Labor, Health and Human Services (LHHS) appropriations for Fiscal Year 2020 draft; provisions related to funding for the Health and Human Services and related agencies
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Zoe |
Aldrich |
|
N/A |
|
Daniel |
Cramer |
|
N/A |
|
Jonathan |
Daniels |
|
N/A |
|
Mary |
Dwight |
|
N/A |
|
David |
Elin |
|
N/A |
|
Victoria |
Gemme |
|
N/A |
|
Katherine |
Haswell |
|
N/A |
|
Sara |
Singleton |
|
N/A |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 2113: Prescription Drug STAR Act; all provisions
Ways & Means and Energy & Commerce discussion draft on capping Medicare Part D out-of-pocket costs; all provisions
S. 475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019; all provisions
S. 1712: Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019; all provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Daniels |
|
N/A |
|
Mary |
Dwight |
|
N/A |
|
David |
Elin |
|
N/A |
|
Victoria |
Gemme |
|
N/A |
|
Sara |
Singleton |
|
N/A |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 3: Lower Drug Costs Now Act of 2019; all provisions
H.R. 987: Strengthening Health Care and Lowering Prescription Drug Costs Act; all provisions
H.R. 2113: Prescription Drug STAR Act; all provisions
H.R. 2296: FAIR Drug Pricing Act of 2019; all provisions
Ways & Means and Energy & Commerce discussion draft on capping Medicare Part D out-of-pocket costs; all provisions
S. 475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019; all provisions
S. 2543 - Prescription Drug Pricing Reduction Act of 2019; all provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Daniel |
Cramer |
|
N/A |
|
Jonathan |
Daniels |
|
N/A |
|
Mary |
Dwight |
|
N/A |
|
David |
Elin |
|
N/A |
|
Sara |
Singleton |
|
N/A |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |